Cargando…
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole. The efficacy of these antibiotics for treatment of...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004428/ https://www.ncbi.nlm.nih.gov/pubmed/29942295 http://dx.doi.org/10.3389/fmicb.2018.01256 |